The comparative evidence basis for the efficacy of second-generation antidepressants in the treatment of depression in the US: A Bayesian meta-analysis of Food and Drug Administration reviews
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 235, 393-398
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010PLOS Medicine, 2013
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- The Costs of DepressionPsychiatric Clinics of North America, 2012
- Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug AdministrationPLOS Medicine, 2008
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- Contradicted and Initially Stronger Effects in Highly Cited Clinical ResearchJAMA, 2005
- Why Isn't Bupropion the Most Frequently Prescribed Antidepressant?The Journal of Clinical Psychiatry, 2005
- Incidence and Duration of Side Effects and Those Rated as Bothersome With Selective Serotonin Reuptake Inhibitor Treatment for DepressionThe Journal of Clinical Psychiatry, 2004
- Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval ReportsNeuropsychopharmacology, 2002
- Statistical methods in psychology journals: Guidelines and explanations.American Psychologist, 1999